Invention Application
- Patent Title: SLFN11 AS BIOMARKER FOR AML
-
Application No.: US15525623Application Date: 2015-11-13
-
Publication No.: US20170314077A1Publication Date: 2017-11-02
- Inventor: David Robert MICKLEM , Monica HELLESOY , Linn Hodneland NILSSON
- Applicant: BERGENBIO AS
- Applicant Address: NO Bergen
- Assignee: BERGENBIO AS
- Current Assignee: BERGENBIO AS
- Current Assignee Address: NO Bergen
- Priority: GB1420239.4 20141114
- International Application: PCT/EP2015/076603 WO 20151113
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/50 ; A61K31/502 ; G01N33/574 ; C07K14/47
Abstract:
The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.
Information query
